Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-04-16

Immunopathogenesis and immunotherapy of chronic arthritis

Objetivo

Four areas of immunological research are particularly promising for possible immunotherapy of chronic arthritis. These are T-cell biology (1), definition of triggering and target antigens (2), immunogenetics (3) and cytokine research (4). In all four areas research is presently being conducted in many institutes from several European countries, and in all areas the need for better communication and coordination was unanimously felt to be urgently needed. In each of these four areas specific objectives have been formulated for a Concerted Action which has been planned for three years.

It should be stressed that these research areas are strongly interrelated and one of the main objectives of this concerted action is to achieve good communication between the scientists involved in several aspects as well as optimal coordination of the different activities. To this purpose two sets of specific objectives which are primarily organizational have been added to the objectives described for these 4 research areas. These are: coordination and centralization of pre-clinical research in non-human primates (5) and standardization of clinical trials (6).
A working relationship has been established between basic researchers, clinicians and companies in Europe interested in immunotherapy of rheumatoid arthritis (RA). Four areas of research are: T-cell biology; definition of triggering and target antigens; immunogenetics; cytokine research.

T-cell biology:
Monoclonal anti T-cell antibodies were produced, in particular antibody MT412 which has high affinity and specificity for the V1 domain of the CD4 molecule and low antigen modulating activity. A mouse/human chimeric form of the antibody was prepared consisting of the human IgG1 constant region of the heavy chain and of the constant region of the kappa light chain clinical trials have shown positive effects.
A study of therapeutic T-cell vaccination using T-cell autologous clones or lines from synovium or synovial fluid showed no clear clinical improvement.

Definition of triggering and target antigens and immunomanipulation:
Many participating laboratories were supplied with various hsp60 containing preparations to study the relevance of these molecules in both experimental models of arthritis and in human chronic arthritis. In children with juvenile rheumatoid arthritis responses of synovial T-lymphocytes to human hsp60 turned out to be most prominent, especially in patients with oligoarticular forms of arthritis. Since this form of arthritis is a spontaneously remitting form of the disease, the findings suggest that responses to endogenous hsp60 are part of regulatory T-cell control.

Immunogenetics:
Repositories have been established for cells from multiplex RA families and human lencocyte antigen (HLA) class II transfectants for distribution to European researchers for genetic and functional studies.

Interference with cytokines:
A common European standard for cytokine determination in fluids derived from arthritic patients has been agreed.

Standardization of clinical trials:
Two simple clinical assessments and one laboratory determination have been agreed for the study of drugs in RA.
1. T cell biology

1.1 Immune intervention with monoclonal anti-T cell antibodies
- consensus on the choice of specific antibodies for treatment.
- standardization of therapeutic antibodies
- standardization and evaluation of clinical trials aimed at therapy development

1.2 Therapeutic T cell vaccination
- protocol development and standardization
- repository for cells, vaccines, sera and other patient materials

2. Definition of triggering and target antigens and immunomanipulation
- to evaluate the molecular and immunological interrelationships between the various experimental models of arthritis induced by bacterial antigens in which heat shock proteins may be involved
- to coordinate the production and distribution to participants of bacterial and human heat shock proteins

3. Immunogenetics
- coordination of HLA typing of patients and cells included in the different trials and studies and standardization of the techniques used
- coordination of functional studies

4. Interference with cytokines
- standardization of cytokines used among members %l - distribution of cytokines
- standardization of measurements of cytokines and cytokine receptors
- banks of cells, serum and synovial fluids derived from a defined patient group
- pre-trial investigations with potential cytokine inhibitors

5. Preclinical research in non-human primates

- pre-clinical testing of promising immunotherapeutical modalities

6. Standardization of clinical trials
- to prepare a recommended standard protocol
- the introduction and evaluation of novel ways of measuring disease activity.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..

Para utilizar esta función, debe iniciar sesión o registrarse

Programa(s)

Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.

Tema(s)

Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.

Datos no disponibles

Convocatoria de propuestas

Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.

Datos no disponibles

Régimen de financiación

Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.

CON - Coordination of research actions

Coordinador

University Hospital Building I, E3-Q
Aportación de la UE
Sin datos
Dirección
PO Box 9600
2300 RC Leiden
Países Bajos

Ver en el mapa

Coste total

Los costes totales en que ha incurrido esta organización para participar en el proyecto, incluidos los costes directos e indirectos. Este importe es un subconjunto del presupuesto total del proyecto.

Sin datos
Mi folleto 0 0